source
- Gilead signs $1.9 billion deal with Vir Biotechnology to license dual-masked T-cell engagers for oncologyGilead Sciences announced a licensing agreement with Vir Biotechnology to access Vir's dual-masked PRO-XTEN T-cell engager platform for oncology. Under the deal, Vir will discover, design and opti…
- iOnctura’s roginolisib shows encouraging phase 1 results in metastatic uveal melanomaiOnctura, a spinout of Merck KGaA, reported data from a two‑part phase 1 trial of its PI3K delta inhibitor roginolisib in patients with advanced solid and hematologic cancers, including a cohort of…